NCT02852837View on ClinicalTrials.gov

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 26, 2016

Primary Completion Date

December 13, 2019

Study Completion Date

December 13, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab

Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.

Trial Locations (5)

Unknown

Beijing

Hangzhou

Shanghai

Suzhou

Tianjin

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02852837 - Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy | Biotech Hunter | Biotech Hunter